文献速递神经核医学放射性药物与辐射防护

18F-FE-PE2I多巴胺转运体放射性配体在人体内的全身生物分布与剂量学

Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects.
PubMed 文献 · J Nucl Med · 2018-01-18

研究纳入5名健康志愿者,平均注射2.5 MBq/kg的18F-FE-PE2I后行系列PET/CT显像、采血和尿液收集,计算器官吸收剂量与有效剂量。肝脏在注射后30分钟内活度浓度最高(0.9%-1.2% ID/100 g),后期胆囊最高;尿排泄占23%-34%(均值28%)。膀胱吸收剂量最高(119 μGy/MBq),肝次之(46 μGy/MBq);有效剂量为23 μSv/MBq(范围19-28 μSv/MBq),200 MBq时有效剂量为4.6 mSv。有效剂量与其他常用PET显像剂及DAT显像剂处于同一数量级,结合既往报道的良好DAT显像与定量特性,表明18F-FE-PE2I是适合DAT显像的放射性配体。

要点

  • 5名健康志愿者注射18F-FE-PE2I(平均2.5 MBq/kg)后行全身PET/CT,计算17个器官的吸收剂量。
  • 尿排泄占注射活度的23%-34%(均值28%);膀胱吸收剂量最高为119 μGy/MBq,肝脏为46 μGy/MBq。
  • 有效剂量为23 μSv/MBq(范围19-28 μSv/MBq),200 MBq时有效剂量为4.6 mSv。

核心结论

  • 18F-FE-PE2I的有效剂量与其他常用PET显像剂及DAT显像剂处于同一数量级。
  • 合理的有效剂量结合既往报道的良好DAT显像与定量特性,表明18F-FE-PE2I是适合DAT显像的放射性配体。

研究设计与样本

  • 研究纳入5名健康志愿者,平均注射活度为2.5 MBq/kg的18F-FE-PE2I。
  • 注射后立即行3次从头到大腿的PET扫描,并在注射后0.5至6小时之间行4次全身PET/CT扫描。
  • 结合全身扫描采血并收集注射后6小时内的全部尿液,在17个器官勾画感兴趣区,计算时间-活度曲线下面积获得器官总衰变数,使用IDAC软件计算器官吸收剂量和有效剂量。

主要发现

  • 注射后30分钟内肝脏活度浓度最高,为0.9%-1.2%注射活度/100 g;后期胆囊浓度最高,为1.1%-0.1%注射活度/100 g。
  • 经尿液排泄的活度范围为23%-34%,均值为28%。
  • 膀胱吸收剂量最高,为119 μGy/MBq;肝脏次之,为46 μGy/MBq。
  • 有效剂量为23 μSv/MBq(范围19-28 μSv/MBq),给予200 MBq活度时有效剂量为4.6 mSv。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4'-methyl-phenyl) nortropane (18F-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for 18F-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of 18F-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. Methods: Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time-activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. Results: The highest activity concentration was observed in the liver (0.9%-1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%-0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 μGy/MBq), followed by the liver (46 μGy/MBq). The effective dose was 23 μSv/MBq (range, 19-28 μSv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. Conclusion: The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that 18F-FE-PE2I is a suitable radioligand for DAT imaging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lizana H, Johansson L, Axelsson J, et al. Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects. J Nucl Med. 2018. PMID: 29348315. doi:10.2967/jnumed.117.197186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。